Well explore the GLP-1 pathway and its significance in maintaining optimal health
Your expert partner for compliance, inspections, and sustainable growth
Patients with well-managed hypertension, diabetes, or cardiovascular disease may use the platform if their provider performs appropriate screening
[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Fernandes A.B., Alves da Silva J., Almeida J., Cui G., Gerfen C.R., Costa R.M., Oliveira-Maia A.J
Ethics declarations Ethical approval and consent to participate Not applicable (review of the literature)
During the mean observation period of 3.3 years, semaglutide at 2.4 mg per week resulted in a mean weight loss of 9.39% from baseline and a 20% reduction in the risk of MACE (HR 0.80, 95% CI 0.720.90), especially a 28% reduction in the risk of myocardial infarction (HR 0.72, 95% CI 0.610.85), compared with that in the placebo group